Blood Adv
Real-World Experience: Idecabtagene Vicleucel in Older Patients With Multiple Myeloma
Kalariya NM, Hildebrandt MAT, Hansen DK, et al
In this multicenter retrospective study, the authors assessed clinical outcomes along with frailty and geriatric characteristics (eg, comorbidities, polypharmacy, falls, neuropathy, organ dysfunction, performance status) in 156 patients aged <65 years and ≥65 years who received commercial idecabtagene vicleucel. Similar safety and efficacy were reported in younger and older patients, with no inferior overall outcome caused by frailty and geriatric characteristics.
Previous Article
- • 3-Year Follow-Up From the Randomized, Phase 3 TRANSFORM Study
- • Final Results of the Phase 2 PILOT Study in Relapsed/Refractory Large B-Cell Lymphoma
- • Case Series: Lisocabtagene Maraleucel for Richter’s Transformation
- • Real-World Analysis of Lisocabtagene Maraleucel for Relapsed/Refractory Large B-cell Lymphoma
- • Implementation of a Lisocabtagene Maraleucel Outpatient Monitoring Program
- • Lisocabtagene Maraleucel Versus Second-Line Chemotherapy Regimens in the Real World
- • Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma
- • Idecabtagene Vicleucel in Patients With Relapsed/Refractory Multiple Myeloma
- • Outcomes of Older Adults and Frail Patients Treated With Idecabtagene Vicleucel
- • Idecabtagene Vicleucel for Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
- • KarMMa-3 Analyses: Idecabtagene Vicleucel in Triple Class-Exposed RRMM
- • Real-World Experience: Idecabtagene Vicleucel in Older Patients With Multiple Myeloma
